Answers are grounded in this paper and cite their sources.
Introduction Myeloperoxidase (MPO) is a key neutrophil heme peroxidase that contributes to antimicrobial oxidative killing. Emerging evidence implicates MPO in diverse inflammatory disorders, including atherosclerosis, autoimmune diseases, and neurodegenerative diseases. Since inherited MPO - deficiency is typically compatible with preserved host defense, inhibition or genetic deletion of MPO represents a promising strategy to mitigate MPO-driven tissue injury. Methods Human HSPCs were edited using CRISPR-Cas9 to generate MPO -knockout ( MPO -KO) neutrophils, followed by in vitro differentiation. We systematically evaluated canonical neutrophil effector functions to determine which of them require MPO. Additionally, RAG2 -KO was generated and used as a control for knockout procedure. Results MPO-KO did not significantly impair major neutrophil effector functions, including neutrophil elastase activity, fMLP-induced NE and MMP9 degranulation, phagocytosis of E . coli and S. aureus bioparticles, and superoxide production. In contrast, MPO-dependent chlorination was abolished and PMA-induced neutrophil extracellular trap (NET) release was profoundly reduced in MPO-KO neutrophils, while RAG2-KO control cells retained all of these functions. Conclusion This strategy may offer a durable means to attenuate MPO-driven inflammatory damage, warranting further preclinical evaluation in relevant disease models.
No takes yet. Share an insight, caveat, or question.
Baron et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: